OncoMethylome Sciences S.A.

https://www.oncomethylome.com

OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, Schering-Plough Corp., Millipore Corporation's BioScience Division, and EXACT Sciences Corp. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands). *

	Start	2003-07-14 renamed
	End	2010-10-06 renamed
	Group	MDxHealth (Group)
	Today	MDxHealth S.A. (Nasdaq/Euronext: MDXH)
	Predecessor	OncoGenome Sciences
	Successor	MDxHealth S.A. (Nasdaq/Euronext: MDXH)
	Industry	diagnostic test, cancer
	Industry 2	DNA methylation technology

	Region	Liège (Lüttich)
	Country	Belgium
	Street	11 Avenue de l’Hopital Tour 5 GIGA niveau +3
	City	4000 Liège
	Tel	+32-4-364-2070
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	2,641,000 (revenues, consolidated (2007) 2007-12-31)
	Profit	-9,975,000 (2007-12-31)
	Cash	27,175,000 (2008-03-31)

		* Document for »About Section«:

		Record changed: 2024-02-12